STUDresearch · Peptide
GDF-11
Also known as
GDF11 · growth differentiation factor 11
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ
Growth factors / muscle
Systemic — a circulating TGF-β-family growth factor; research and self-reports concern whole-body exposure, not an organ-specific capsule.
What people say
GDF11 is a circulating TGF-β-family growth factor closely related to myostatin/GDF8, not a short organ bioregulator. Aging claims remain scientifically disputed.
Doses people talk about
That orders-of-magnitude conflict may reflect product, unit or protocol differences. It is preserved as disagreement, not converted into a progression.
How it may feel
Long-term accounts conflict: one user described unusual endurance but no concrete evidence, while another five-year tracker found no claimed benefit and worse HRV. One AFIB episode followed a later interval change, with causation uncertain.
Tracked self-log, initial phaseUp to 300 pg; later 150 pg weekly
One author began in May 2020, reduced after six months and reported no tracked improvement; rapamycin, metformin, diet and exercise confounded attribution.
Tracked self-log, later phase75 pg every 2 weeks
The same author described this by January 2021 and a first AFIB episode about two weeks later, explicitly without claiming causation.
Legacy experimental folklore~10–100 mcg SC
Preserved older chart range with extreme identity, purity and unit uncertainty; not reconciled with the inspected picogram logs.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- AccountsNo noticeable change or claimed endurance gains
- Long-term trackerNo promoted reaction-time or HRV gains across 5 years
Cycles people discuss
Reviewed reports describe prolonged use followed by smaller weekly or biweekly amounts, not a validated seasonal cycle. The old 10–20-day course language belongs to another peptide culture.
Timing
No relevant human parent-protein half-life was found. Mouse studies used defined recombinant products and dose-specific endpoints; a one-hour tissue readout is not clearance or a community dosing interval.
Stacks
GDF11 self-reports often sit beside rapamycin, metformin, diet and exercise. Solo attribution is therefore weak, and broad multi-bioregulator language does not establish a GDF11 stack.
Watch for
Uncertain effects and adverse signal: Vendor literature may claim good tolerability, but a five-year tracked self-report found no claimed improvements and reported a first AFIB episode about two weeks after moving to 75 pg every two weeks; the author did not claim causation. Animal dose-response work found severe cachexia and death at 5 mg/kg/day.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A dependable human parent-GDF11 half-life was not established by the checked evidence.
One primary study measured heart signaling one hour after 0.5 mg/kg IV recombinant GDF11 in adult mice. That endpoint shows activity at one time point, not an elimination curve.
Recombinant product potency varies; endogenous assay cross-reactivity with GDF8 complicates concentration claims; no gray-market formulation PK.
- Walker et al. — Structural basis for potency differences between GDF8 and GDF11 (opens in a new tab)Full text, Results and Methods: adult male mice received 0.5 mg/kg GDF11 by tail-vein IV; hearts were collected one hour later for pSMAD2. In-vitro potency and product-source differences are also described.Mouse single-time-point pharmacodynamics, not human PK or a half-life measurement; recombinant protein source and activity matter.
- Schafer et al. — Quantification of GDF11 and myostatin in human aging and cardiovascular disease (opens in a new tab)Full text abstract, methods and discussion: immunoplexed LC-MS/MS separated GDF11 from myostatin in cross-sectional human samples and did not find GDF11 declining with age.Endogenous cross-sectional biomarker study, not exogenous dosing, pharmacokinetics, benefit or causality. Cardiovascular surgical cohort associations do not define treatment effects.
Felt duration people report
No repeatable single-dose felt window emerged from the inspected accounts.
Reports span no noticeable change, claimed endurance without concrete evidence and five years of tracking without the promoted reaction-time or HRV improvements.
Tiny sample, unverified products, changing intervals and heavy co-use. A later AFIB episode is important but does not establish causation or duration.
- GDF-11 supplementation in addition to Rapamycin (opens in a new tab)Actual thread content: Steven_Ow posts 1 and 9 and DrT post 12, Nov. 2022–June 2023. Reports include little felt difference, claimed yard-work endurance, three years of use, uncertain reaction-time practice effect and no concrete evidence.Unverified products, self-selected users and substantial rapamycin/exercise/genetic confounding. Thread also contains preparation material that was reviewed but not carried into this card.
- Anyone trying something a little more edgy? — GDF11 posts (opens in a new tab)Actual Discourse post stream: LukeMV post 212; Paul posts 218, 221 and same-author update 228; replies 219–230, Sept. 2024–Jan. 2025. Amounts, five-year tracking, HRV/reaction-time findings and uncertain AFIB timing were read together.Individual retrospective reports with unverified formulation and units, multiple concurrent interventions and no blinded control. Later commenters' causal speculation was not adopted.
Other context in this card
- Harper et al. — GDF11 decreases pressure overload induced hypertrophy, but can cause severe cachexia and premature death (opens in a new tab)Full text abstract, methods and discussion: C57BL/6 mice received daily recombinant GDF11 at 0.5, 1.0 or 5.0 mg/kg for up to 14 days; 5.0 mg/kg caused severe weight loss and death.Young mouse pressure-overload model and recombinant product; not human safety, a community dose conversion or parent-protein PK.
What people say
- Aging-factor narrative: Community interest grew from claims that replacing a youthful circulating factor might improve heart, muscle or brain aging. Later assay work and animal studies produced conflicting findings; this is not an established human rejuvenation effect. forumtrial
- What is thinner: Large modern multi-center RCTs are often absent for the specific peptide brand story. forum
- Energy / performance reports: One long-term user said there was no concrete evidence of benefit despite good energy and exercise capacity; another five-year tracker said reaction-time and HRV claims did not hold up. Training, practice effects, rapamycin and metformin were major confounders. forumanecdote
- Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
- Measurement controversy: GDF11 and myostatin/GDF8 are difficult to separate with some antibodies and aptamers. Human mass-spectrometry work did not find an age-related GDF11 decline, so “replace what aging removes” is not a settled premise. trial
Doses people talk about
- Community experimental talk: when sold, often ~10–100 mcg SC folklore — identity/purity risk is extreme. forum
- Frequency: intermittent experimental pins more than chronic daily validated use. forum
- Framing: GDF11 controversy + research-chem hype; human dose not standardized. forum
- No accepted clinical daily dose for “anti-aging GDF11.” trial
How it may feel
- Early experience: Inspected GDF11 accounts do not establish a typical first-week sensation. One long-term user recalled that a prominent protocol developer reported severe early symptoms while finding an amount; another user later reported no clear subjective effect. forum
- Courses: The retained 10–20-day seasonal-course language belongs to broader bioregulator culture, not established GDF11 practice. Inspected GDF11 reports instead described months-to-years of tiny injections with shifting intervals. forum
- Day 1: The reviewed accounts do not establish what most people feel after one GDF11 dose. Reported long-term observations ranged from little subjective change to claimed endurance, with no blinded comparator. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: This is not an established benefit checkpoint. One author reported a first AFIB episode about two weeks after changing to 75 pg every two weeks, while explicitly saying the relationship was uncertain. forumanecdote
Cycles people discuss
- Course culture: Short-on, long-off seasonal language is inherited bioregulator context, not a verified common GDF11 pattern. The reviewed reports instead describe prolonged use, later reductions and maintenance spacing. forum
- Adverse-event context: In one five-year account, no claimed improvements emerged and a first AFIB episode occurred after a later interval change; the author did not assign causation. That report describes a decision context, not a dosing rule. forumanecdote
- Intervals vary: The reviewed accounts include weekly and every-two-week maintenance after an initial prolonged phase, plus multi-year use. They do not establish a common weeks-on/weeks-off calendar. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
Timing
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Not a short bioregulator: GDF11 is a secreted TGF-β-family growth factor. The reviewed mouse studies used recombinant proteins with product- and dose-dependent activity, but they did not establish a human parent-protein half-life for gray-market material. trial
- Published PK gap: No relevant human exogenous-GDF11 concentration-time study was identified in the checked evidence. A one-hour mouse heart signaling readout after IV recombinant protein is a pharmacodynamic sampling point, not a half-life. trial
More on what it is
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for GDF-11, not proof it works for you. forum
- What it is: GDF11 is a secreted TGF-β-superfamily growth factor closely related to myostatin/GDF8. Its mature signaling domains are highly similar, which has complicated assays and helped fuel the aging-factor controversy. It is not a short Khavinson/cytomedine bioregulator. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Multi-bioregulator stacks: Often combined by organ system in protocols. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Uncertain effects and adverse signal: Vendor literature may claim good tolerability, but a five-year tracked self-report found no claimed improvements and reported a first AFIB episode about two weeks after moving to 75 pg every two weeks; the author did not claim causation. Animal dose-response work found severe cachexia and death at 5 mg/kg/day. forumanimal
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.